Helicobacter Pylori Infection and Extra-Gastric Autoimmune Disorders

Dear Colleagues,

Helicobacter pylori infection is the most common cause of gastritis, and is it etiologically involved in gastric ulcers, duodenal ulcers, gastric adenocarcinoma, and primary gastric B-cell lymphoma. Helicobacter pylori infection also plays a role in non-ulcer dyspepsia. Helicobacter pylori-related diseases are among the most prevalent in the world, and evidence obtained in recent decades suggests a causal role of Helicobacter pylori infection in the occurrence of pathological conditions involving organs and systems outside the gastric environment. The extension and magnitude of these manifestations vary according to the tissues involved, although, in general, they are primarily the result of a long-lasting low-grade inflammation and/or autoimmune processes, via several mechanisms. While its role in growth retardation, idiopathic thrombocytopenic purpura, iron-deficiency anemia, and vitamin 12 deficiency has already been recognized, emerging evidence suggests that Helicobacter pylori may increase the risk of blood hypertension, cardiovascular disease, metabolic syndrome, autoimmune thyroiditis, and neurodegenerative, respiratory, skin, rheumatic diseases, and several other disorders. The scientific literature regarding the "extra-gastric manifestations" of Helicobacter pylori infection is currently gaining growing interest among researchers. A better understanding of the role of this bacteria in specific disorders may induce recommendations for a proactive approach to the testing and treatment of Helicobacter pylori including outreach with family members of individuals diagnosed with active infection as well as high-risk local populations such as immigrants. Treatment with antibiotics may have many additional positive outcomes including a beneficial effect on infections other than Helicobacter pylori (e.g., periodontal disease, etc.).

Prof. Dr. Maria Pina Dore
Dr. Giovanni Mario Pes
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Helicobacter pylori
• extra-gastric diseases
• inflammation
• autoimmune-disorders
• treatment challenges
• molecular mimicry
• modern diagnosis